Erik Berntorp
261 – 270 of 329
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2003
-
Mark
Limited protective effect of the CCR5 Delta 32/CCR5 Delta 32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
(
- Contribution to journal › Article
-
Mark
Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.
(
- Contribution to journal › Article
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
(
- Contribution to journal › Article
- 2002
-
Mark
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients
(
- Contribution to journal › Article
-
Mark
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
(
- Contribution to journal › Article
-
Mark
Progress in haemophilic care: ethical issues.
(
- Contribution to journal › Article
-
Mark
The prognostic value of global haemostatic tests in the intensive care unit setting.
(
- Contribution to journal › Article
-
Mark
Clinical outcomes and resource utilization associated with haemophilia care in Europe
(
- Contribution to journal › Article
-
Mark
Unresolved issues in prophylaxis
(
- Contribution to journal › Article
-
Mark
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
(
- Contribution to journal › Article